Why Is Medical Device Maker Integra LifeSciences Stock Falling On Monday?

Zinger Key Points
  • Integra LifeSciences updates 2024 guidance to include the Acclarent acquisition, adding ~$80 million and SurgiMend and PriMatrix relaunch.
  • The company is evaluating the timeline to address the findings related to Boston facility product recall and resume commercial production.

Monday, Integra LifeSciences Holdings Corporation IART reported first-quarter revenues of $368.9 million, down 3.1% Y/Y on a reported basis and 2.5% on an organic basis, beating the consensus of $361.96 million and the management guidance of $360 million to $365 million.

Revenue increased by 1.6% on an organic basis, excluding Boston.

Integra Lifesciences reported an adjusted EPS of $0.55, which is in line with the consensus and lower than $0.74 a year ago. The management had forecasted first-quarter adjusted EPS of $0.53-$0.57.

The company reported adjusted gross margin of 64.4%, compared to 67.3% in the prior year.

Adjusted EBITDA for the first quarter of 2024 was $71.8 million, or 19.5% of revenue, compared to $92.3 million, or 24.2% of revenue, in the prior year.

Codman Specialty Surgical revenues were $256.4 million, representing reported growth of 3.3% and organic growth of 4.4% Y/Y.

Tissue Technologies revenues were $112.4 million, down 15.3% on a reported and organic basis, primarily driven by the impact of the Boston product recall. 

Tissue Technologies sales were down 4.4%, excluding Boston

The company is evaluating the timeline to address the findings related to the Boston facility product recall and resume commercial production.

Guidance: Integra LifeSciences expects second-quarter revenue of $411 million-$416 million versus the consensus of $395.8 million, representing reported growth of 7.8%-9.1% and organic growth of 1.3%-2.6%, reflecting the better than expected first quarter performance and the completion of the Acclarent acquisition.

The company forecasts adjusted EPS of $0.60-$0.65 versus the consensus of $0.75.

For fiscal year 2024, the company is updating its revenue and adjusted EPS expectations to $1.672 billion-$1.687 billion and $3.01 to $3.11, respectively. 

Integra LifeSciences updates its fiscal year 2024 revenue guidance to $1.672 billion-$1.687 billion compared to prior guidance of $1.603 billion-$1.618 billion and the consensus of $1.616 billion.

The company lowered adjusted EPS forecast of $3.01-$3.11 (prior $3.15-$3.25) versus the consensus of $3.19.

The revenue range represents reported growth of 8.4% to 9.4%, with organic growth of 3.3% to 4.3%, reflecting the completion of the Acclarent acquisition and the removal of approximately $10 million of revenue from the relaunch of SurgiMend and PriMatrix beginning in the second half.

Price Action: IART shares are down 17.40% at $23.87 at last check Monday.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareTop StoriesMoversGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!